WO2011138557A3 - Use of an anti-cd71 antibody for preparing a medicament - Google Patents

Use of an anti-cd71 antibody for preparing a medicament Download PDF

Info

Publication number
WO2011138557A3
WO2011138557A3 PCT/FR2011/051005 FR2011051005W WO2011138557A3 WO 2011138557 A3 WO2011138557 A3 WO 2011138557A3 FR 2011051005 W FR2011051005 W FR 2011051005W WO 2011138557 A3 WO2011138557 A3 WO 2011138557A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
medicament
preparing
antigen
fragment
Prior art date
Application number
PCT/FR2011/051005
Other languages
French (fr)
Other versions
WO2011138557A2 (en
Inventor
Laurence Boumsell
Original Assignee
Monoclonal Antibodies Therapeutics Mat-Biopharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monoclonal Antibodies Therapeutics Mat-Biopharma filed Critical Monoclonal Antibodies Therapeutics Mat-Biopharma
Priority to US13/696,097 priority Critical patent/US20130216476A1/en
Priority to EP11723558A priority patent/EP2566511A2/en
Publication of WO2011138557A2 publication Critical patent/WO2011138557A2/en
Publication of WO2011138557A3 publication Critical patent/WO2011138557A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to the use of an anti-CD71 monoclonal antibody or of a fragment of an abovementioned antibody, capable of binding to the CD71 antigen, for preparing a medicament for preventing or treating myelomas.
PCT/FR2011/051005 2010-05-03 2011-05-03 Use of an anti-cd71 antibody for preparing a medicament WO2011138557A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/696,097 US20130216476A1 (en) 2010-05-03 2011-05-03 Use of an anti-cd71 antibody for preparing a medicament
EP11723558A EP2566511A2 (en) 2010-05-03 2011-05-03 Use of an anti-cd71 antibody for preparing a medicament

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1053426 2010-05-03
FR1053426A FR2959416B1 (en) 2010-05-03 2010-05-03 USE OF ANTI-CD71 ANTIBODIES FOR THE PREPARATION OF A MEDICINAL PRODUCT

Publications (2)

Publication Number Publication Date
WO2011138557A2 WO2011138557A2 (en) 2011-11-10
WO2011138557A3 true WO2011138557A3 (en) 2011-12-29

Family

ID=42671926

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2011/051005 WO2011138557A2 (en) 2010-05-03 2011-05-03 Use of an anti-cd71 antibody for preparing a medicament

Country Status (4)

Country Link
US (1) US20130216476A1 (en)
EP (1) EP2566511A2 (en)
FR (1) FR2959416B1 (en)
WO (1) WO2011138557A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI689314B (en) 2010-11-30 2020-04-01 建南德克公司 Low affinity blood brain barrier receptor antibodies and uses therefor
US9696312B2 (en) 2011-09-02 2017-07-04 The Trustees Of Columbia University In The City Of New York Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand
PL3292149T3 (en) 2015-05-04 2022-03-21 Cytomx Therapeutics, Inc. Activatable anti-cd71 antibodies, and methods of use thereof
US10765742B2 (en) 2015-07-17 2020-09-08 The Trustees Of Columbia University In The City Of New York Methods of treating CD166-expressing cancer
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
UA125898C2 (en) 2016-03-04 2022-07-06 Джн Байосайєнсіз, Ллк Antibodies to tigit
WO2018165619A1 (en) 2017-03-09 2018-09-13 Cytomx Therapeutics, Inc. Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
WO2019173771A1 (en) 2018-03-09 2019-09-12 Cytomx Therapeutics, Inc. Activatable cd147 antibodies and methods of making and use thereof
CN114650844A (en) 2019-09-23 2022-06-21 西托姆克斯治疗公司 anti-CD 47 antibodies, activatable anti-CD 47 antibodies, and methods of use thereof
WO2021163033A1 (en) * 2020-02-10 2021-08-19 The Trustees Of Columbia University In The City Of New York Compositions and methods for detecting cells undergoing ferroptosis using an antibody
JP2023528036A (en) 2020-06-02 2023-07-03 アーカス バイオサイエンシズ インコーポレイティド Antibody to TIGIT
CN116120451A (en) * 2021-06-17 2023-05-16 南京蓝盾生物科技有限公司 anti-CD 70 internalizing antibodies, antibody conjugates and uses thereof
TW202328187A (en) 2021-09-01 2023-07-16 美商百健Ｍａ公司 Anti-transferrin receptor antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094364A2 (en) * 2004-03-31 2005-10-13 Chimeric Technologies, Inc. Iga antibody protein as a cytotoxic drug
WO2007000671A2 (en) * 2005-06-15 2007-01-04 Monoclonal Antibodies Therapeutics Anti-cd71 monoclonal antibodies and uses thereof for treating malignant tumour cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094364A2 (en) * 2004-03-31 2005-10-13 Chimeric Technologies, Inc. Iga antibody protein as a cytotoxic drug
WO2007000671A2 (en) * 2005-06-15 2007-01-04 Monoclonal Antibodies Therapeutics Anti-cd71 monoclonal antibodies and uses thereof for treating malignant tumour cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAETLE R ET AL: "Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH FEB 1996 LNKD- PUBMED:9816167, vol. 2, no. 2, February 1996 (1996-02-01), pages 253 - 259, XP002600166, ISSN: 1078-0432 *

Also Published As

Publication number Publication date
FR2959416B1 (en) 2012-06-22
US20130216476A1 (en) 2013-08-22
WO2011138557A2 (en) 2011-11-10
EP2566511A2 (en) 2013-03-13
FR2959416A1 (en) 2011-11-04

Similar Documents

Publication Publication Date Title
WO2011138557A3 (en) Use of an anti-cd71 antibody for preparing a medicament
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
IL245274A0 (en) Monoclonal antibodies against her2 epitope
UA101487C2 (en) Humanized b-ly1 antibody formulation
NZ602294A (en) Monoclonal antibodies against c-met
NZ621170A (en) Anti-human cd52 immunoglobulins
WO2011131786A3 (en) Process for preparing an immunoglobulin composition
MX2013009362A (en) Antibody against the csf-1r.
IL222359A0 (en) Monoclonal antibodies against her2 antigens, and uses therefor
WO2012125569A3 (en) Anti-cd40 antibodies and uses thereof
WO2010145792A8 (en) Bispecific antigen binding proteins
MX352871B (en) Method for decreasing immunogenicity.
MX2013005015A (en) Anti-il-23 antibodies.
NZ621938A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
SG178886A1 (en) Humanized anti-cdcp1 antibodies
AP2011005719A0 (en) Anti-IGF antibodies.
EP2540745A4 (en) Fully humanized anti-her2 antibody, preparation method and use thereof
WO2013043933A3 (en) Cd27l antigen binding proteins
WO2010121093A3 (en) Humanized antibody compositions and methods for binding lysophosphatidic acid
WO2013063613A3 (en) Methods and compositions related to intracellular neutralization by igg
WO2012080926A3 (en) Anti-notch1 antibodies
WO2011075636A3 (en) Wise binding agents and epitopes
WO2011130603A3 (en) Anti-vla-4 antibodies
WO2013009521A3 (en) Methods and compositions for treating asthma using anti-il-13 antibodies
WO2008048519A3 (en) Antibodies that bind cxcr7 epitopes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11723558

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011723558

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13696097

Country of ref document: US